Added to YB: 2026-09-17
Pitch date: 2026-09-15
ABCL [neutral]
AbCellera Biologics Inc.
Author Info
No bio for this author
Company Info
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States.
Market Cap
$3.6B
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
-17.18
P/E
-20.47
EV/Sales
48.59
Sector
Life Sciences Tools and Services
Category
growth
Biotech Conference Coverage: Week 2, Day 1 — Part 1: AbCellera Biologics Inc.
ABCL (update): AbCellera is transitioning from an antibody-discovery platform into a multi-asset therapeutics company. Management was highly confident in ABCL635, describing its Phase II efficacy signal as difficult to imagine missing in later development. The next Phase II study is expected to begin in H2 2027 and potentially support a launch around 2030, but the excerpt does not include the indication, full efficacy data, safety profile or detailed competitive context.
Read full article (1 min)